Full text is available at the source.
Abstract
Semaglutide reduces body mass index by 16.1% in adolescents with obesity.
- More than 20% of adolescents are affected by obesity, which is linked to metabolic disorders and heart disease.
- Conservative treatments have shown limited effectiveness in cases of severe obesity among young people.
- Glucagon-like peptide 1 receptor agonists, particularly semaglutide, show significant improvement in managing adolescent obesity.
- Semaglutide is more effective than liraglutide in enhancing insulin sensitivity.
- Challenges in drug use include high costs and social inequalities impacting health equity.
- Limited data exists regarding the safety and efficacy of Tirzepatide and CagriSema in adolescents compared to adults.
Simplified